BrAD-R13
/ Shanghai Braegen Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of BrAD-R13 Tablets in Chinese Subjects with Alzheimer's Disease
(ChiCTR)
- P1 | N=32 | Not yet recruiting | Sponsor: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of Universit
New P1 trial • Alzheimer's Disease • CNS Disorders
1 to 1
Of
1
Go to page
1